UK Edition

Tuesday, 17 November 2026

Time Trade

Markets, trading & finance — British perspective

Trading

Roche's Wilserdly-Everolimus Wins FDA Approval For ESR1-Mutated Advanced Breast Cancer

Time Trade session note (2026-11-17): Roche 1W Harvesting Gains! Trim Into Strength, Hunt the Next DipRoche (RHHBY) has ripped into the upper region of a rising weekly channel, where I’m looking… Primary source: original at Nasdaq Market Structure (nasdaq.com).

· Nasdaq Market Structure

Roche 1W Harvesting Gains! Trim Into Strength, Hunt the Next DipRoche (RHHBY) has ripped into the upper region of a rising weekly channel, where I’m looking to sell into strength at the marked resistance zone after this vertical leg. From there, my plan is to wait for a deeper pullback toward the mid‑channel / prior breakout area to re‑enter on the long side, u

Roche Holding Ltd

Peers for comparison



Key facts today



The FDA approved Roche’s giredestrant with everolimus for certain advanced breast cancers and authorized a companion diagnostic to identify eligible patients. 1

Company info



Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Holding: Further UpwardRoche Holding shares have recently continued to rise. In our primary scenario, we see price continuing to head toward our red Short Target Zone between CHF 394.30 and CHF 415.49. We expect the magenta wave (B) to peak within this zone. We then anticipate a significant downward movement in the form o

Roche Strengthens Its Bet Against the “Superbug”By Ion Jauregui – Analyst at ActivTrades Zosurabalpin: A New Hope Against Antimicrobial Resistance Swiss pharmaceutical giant Roche (SWX: ROG) has just taken a major step forward in the fight against bacterial resistance: its new antibiotic zosurabalpin is entering Phase 3 clinical trials. The co

Roche vs. Novo Nordisk: Who will suffer the Weight Loss?Roche (ticker: ROG.SW) is losing ground on the stock due to the side effects of its new weight loss pill, CT-996, which is still in the testing phase. After a rally that boosted its shares 40% between May and September, the Swiss drugmaker has seen an 11% drop in its shares in September alone, inclu

Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment. Management Effectiveness: Roche has been around since 1896

Roche: Ready for 120% Growth?We're trying something with Roche here, where we think that we are currently in Wave (5), having recently completed Wave (4). This assessment is better visualized on the daily chart. Hence, we should maintain the 61.8% level for this Wave 4. Anything below would statistically be too low, while above

Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here. Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma. There were only 3 pull backs greater than 30% in the history of the stock. 2002 ~ 2003: -45.33% 2006 ~ 2011: -52.40% 2014 ~ 2018: -30.24% 2022 ~ present: -44.89% It is at the support z

Summarizing what the indicators are suggesting.

An aggregate view of professional's ratings.

Displays a symbol's price movements over previous years to identify recurring trends.

Frequently asked questions



Today, RO trades at 414.0 CHF.

For broader market analysis, dive into the technicals on the Roche Holding Ltd stock price chart and read the latest RO news:
– Roche Secures First U.S. Approval for New Breast-Cancer Pill
– FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
– FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

For broader market analysis, dive into the technicals on the Roche Holding Ltd stock price chart and read the latest RO news:

– Roche Secures First U.S. Approval for New Breast-Cancer Pill

– FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer

– FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

Markets don't sleep, here's what's going on with RO at the moment:
– Roche Secures First U.S. Approval for New Breast-Cancer Pill
– FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
– FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

See more updates in real-time with our News Flow.

See more updates in real-time with our News Flow.

Roche Holding Ltd is scheduled to release its next earnings report on Jan 28, 2027.

Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release

How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts

– Key event: Earnings often drive significant price moves

– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts

– Volatility spike: Price swings can increase before and after the release

– Track upcoming reports in the Earnings Calendar

– Compare actual results with analyst estimates

– Monitor price reaction and volume on Supercharts

RO stock is 0.05% volatile and has beta coefficient of 1.20.

What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable

Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like RO are typically less volatile than smaller companies

Track every detail on Roche Holding Ltd stock chart and check out the list of the most volatile stocks — is Roche Holding Ltd there?

– Volatility: Shows how much the price fluctuates over time

– Beta > 1: More volatile than the market

– Volatility can increase during earnings, news events, or market stress

– Large-cap stocks like RO are typically less volatile than smaller companies

Track every detail on Roche Holding Ltd stock chart and check out the list of the most volatile stocks — is Roche Holding Ltd there?

To understand the RO stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +0.53%
– 1 week — +3.55%
– 1 month — +8.77%

RO all-time low was 111.6 CHF (Sep 21, 2001), and its highest price is 439.2 CHF (Apr 11, 2022). Find more dynamics in the Stock Heatmap and on the Roche Holding Ltd stock chart.

RO all-time low was 111.6 CHF (Sep 21, 2001), and its highest price is 439.2 CHF (Apr 11, 2022). Find more dynamics in the Stock Heatmap and on the Roche Holding Ltd stock chart.

Roche Holding Ltd market capitalization is ‪327.79 B‬, representing the total value of all its outstanding shares (price × shares outstanding).

What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements

What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Roche Holding Ltd stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Roche Holding Ltd stacks up against other companies

– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)

– It reflects how investors value the company today

– It changes constantly with stock price movements

– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns

– Price vs shares: Changes can come from Roche Holding Ltd stock price moves or share count (buybacks, issuance)

– Valuation ratios: Compare market cap with revenue and earnings

– Peer comparison: See how Roche Holding Ltd stacks up against other companies

The safest way to buy Roche Holding Ltd stocks is through a reliable broker. Create an account, fund it, and place a buy order.

You can trade RO directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.

You can trade RO directly from TradingView:

– Choose a broker: Explore our supported trading partners and pick one that fits your needs

– Compare options: View available brokers side by side to evaluate fees and features

– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in

– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.

As of Nov 17, 2026, the company has ‪112.77 K‬ employees.

Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements

See our rating of the largest employers to find more opportunities.

– Company scale: Employee count reflects the size and global reach of the business

– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services

– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements

See our rating of the largest employers to find more opportunities.

Roche Holding Ltd pays dividends, but whether it is a “good” dividend stock depends on its yield and stability rather than dividends alone.

Its recent dividend yield was around 2.92%, with a payout ratio of 60.57%, compared to 3.58% and 93.40% in the previous period.

What to look at when looking for good dividend stocks:
– Dividend yield: Income potential relative to price
– Payout ratio: Sustainability of dividend payments
– Dividend history: Consistency and growth over time
– Earnings strength: Dividends are more reliable when supported by stable profits
– Total return: Combines dividends with stock price performance

Explore all this in Roche Holding Ltd financials.

Its recent dividend yield was around 2.92%, with a payout ratio of 60.57%, compared to 3.58% and 93.40% in the previous period.

What to look at when looking for good dividend stocks:

– Dividend yield: Income potential relative to price

– Payout ratio: Sustainability of dividend payments

– Dividend history: Consistency and growth over time

– Earnings strength: Dividends are more reliable when supported by stable profits

– Total return: Combines dividends with stock price performance

Explore all this in Roche Holding Ltd financials.

Investing in Roche Holding Ltd depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.

First, study Roche Holding Ltd financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency

Then explore our RO technicals – signals based on essential indicators calculations:
– Today — buy
– 1-week — buy
– 1-month — buy

Combine fundamental and technical analysis for better results.

First, study Roche Holding Ltd financials and track their dynamics on the Fundamental Graphs:

– Business fundamentals: Revenue, earnings, and growth trends

– Valuation: P/E ratio, market cap, and how it compares to peers

– Profitability: Margins, return on equity, and cash flow

– Dividends (if any): Yield, payout ratio, and consistency

Then explore our RO technicals – signals based on essential indicators calculations:

Combine fundamental and technical analysis for better results.

Roche Holding Ltd stock ticker depends on the exchange where it’s listed. On the SIX, its primary exchange, Roche Holding Ltd stocks trade under the symbol RO.

About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners

Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion

Learn how to find your desired assets in our Symbol Search.

– Unique identifiers: A ticker is a short code used to find and trade a stock

– Exchange-specific: The same company may have different tickers across exchanges

– Search shortcut: Used on trading platforms, charts, and screeners

– Always check the exchange prefix to avoid confusion

Learn how to find your desired assets in our Symbol Search.

RO earnings for the last half-year are 10.85 CHF per share, whereas the estimation was 10.11 CHF, resulting in a 7.33% surprise. The estimated earnings for the next half-year are 9.70 CHF per share.

How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple periods, not just one

Follow other essential metrics in Roche Holding Ltd financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk

– Compare actual vs estimates: Earnings beats or misses often drive price moves

– Watch market reaction: Price response matters as much as the numbers

– Look at forward guidance: Future estimates signal expected growth

– Track trends: Analyze results across multiple periods, not just one

Follow other essential metrics in Roche Holding Ltd financials:

– Revenue growth: Shows business expansion

– Margins (operating, net): Reflect profitability and efficiency

– Free cash flow: Indicates real cash generation

– Debt levels: Impacts financial stability and risk

Roche Holding Ltd revenue for the last half-year amounts to ‪31.45 B‬ CHF despite the estimated figure of ‪30.43 B‬ CHF. In the next half-year revenue is expected to reach ‪30.63 B‬ CHF.

How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous periods and year-over-year data
– Track trends: One half-year matters less than consistent performance

Follow other essential metrics in Roche Holding Ltd financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses

– Compare actual vs estimates: Revenue beats or misses can move the stock

– Watch market reaction: Price response shows how investors interpret results

– Look at growth: Compare with previous periods and year-over-year data

– Track trends: One half-year matters less than consistent performance

– Earnings (EPS): Profitability per share

– Margins (gross, operating): Efficiency and cost control

– Free cash flow: Cash available after expenses

Yes, you can track Roche Holding Ltd financials in yearly and quarterly reports right on TradingView.

Use our Earnings Calendar to never miss important releases and spot opportunities early.

Use our Earnings Calendar to never miss important releases and spot opportunities early.

RO net income for the last half-year is ‪6.87 B‬ CHF, while the half-year before that showed ‪5.47 B‬ CHF of net income which accounts for 25.61% change.

How to read this data:
– Track changes: Compare net income across periods to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one period: Consistency matters more than a single result

Follow other essential metrics in Roche Holding Ltd financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control

– Track changes: Compare net income across periods to spot trends

– Watch expectations: Compare with estimates to gauge performance

– Check margins: Net income reflects profitability after all expenses

– Look beyond one period: Consistency matters more than a single result

– Earnings per share: Rising EPS over time often points to improving business performance

RO reached its all-time high of 439.2 CHF on Apr 11, 2022. Its all-time low was 111.6 CHF and was reached on Sep 21, 2001.

Explore the Roche Holding Ltd stock price chart to see more price history, and discover companies reaching new all-time highs and lows.

Explore the Roche Holding Ltd stock price chart to see more price history, and discover companies reaching new all-time highs and lows.

Roche Holding Ltd EBITDA is ‪22.07 B‬ CHF, with an EBITDA margin of 36.83%.

EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.

What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures

What to look at next in Roche Holding Ltd statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality

EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.

– Operating strength: Helps assess profitability from core operations

– Efficiency signal: Rising EBITDA often reflects improving business performance

– Comparability: Useful for comparing companies with different capital structures

What to look at next in Roche Holding Ltd statements:

– Revenue growth: Shows whether the business is expanding

– Net income: Captures full profitability after all expenses

– Free cash flow: Shows actual cash generated

– Debt levels: Important when evaluating earnings quality

Analyst forecasts suggest a price range between 250.00 CHF and 500.00 CHF for RO, based on current estimates.

Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions

Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance

– Forecasts show possible scenarios, not guaranteed outcomes

– They're based on multiple analysts’ models and assumptions

– Target prices change with earnings, news, and market conditions

– Use technical analysis: Trend, support/resistance, momentum

– Study fundamentals: Revenue, earnings, margins

– Account for market context: News, macro trends, sector performance